If you’ve been living with what was called polycystic ovarian syndrome (PCOS), or if you’ve spent years being dismissed, misdiagnosed, or told to simply lose weight, you may have seen the news making rounds this month: PCOS has officially been renamed.
It’s now called PMOS: polyendocrine metabolic ovarian syndrome.
One letter changed. A decade-plus of work behind it. And a whole lot of complicated feelings about what it actually means for the people most affected.
Let’s talk about it.
Polycystic ovary syndrome has been a diagnosis since 1935, when researchers first described a condition they believed originated in the ovaries. The name reflected what they thought they were seeing on early imaging: cysts. The problem? Those aren’t actually pathological cysts. They’re normal follicular structures that got misread and mislabeled from the start.
Despite the name, PCOS was never just about ovaries or cysts. It’s a complex endocrine and metabolic condition that affects roughly one in eight people with ovaries worldwide. That’s more than 170 million people of reproductive age globally.
Its reach extends across nearly every system in the body:
And yet, for nearly a century, the name kept pointing everyone’s attention at the ovaries and the “cysts” that aren’t really cysts.
The condition was named polycystic ovarian syndrome. Polycystic. As in, many cysts. As in, that’s the thing we’re calling this. And yet, you did not need to have actually have ovarian cysts to be diagnosed with it.
The most widely used diagnostic framework, known as the Rotterdam criteria, was established in 2003 by a consensus panel of experts. It requires a person to meet two out of three of the following:
Two out of three. Which means you could have irregular periods and elevated androgens with completely unremarkable ovaries on ultrasound and still be diagnosed with PCOS. The name of the thing you were diagnosed with described something you didn’t even have to have.
And it goes further. Even among people who do show the polycystic ovarian appearance on ultrasound, those structures are not actually harmful cysts. They’re small, immature follicles, ie. normal physiological features that look a certain way on imaging. They aren’t the disease. They’re a marker, and not even a required one.
To make things even murkier, the Rotterdam criteria aren’t universally applied in the same way. Different professional organizations have used different frameworks. The NIH criteria, the Androgen Excess Society criteria each weigh the three features differently. A person could be diagnosed under one framework and technically not qualify under another. There has never been a single, airtight, universally agreed-upon definition of this condition. It is, as one clinical resource puts it plainly, “a syndromic diagnosis” with “no specific criteria that diagnose it unequivocally.”
So to recap: the condition was named after cysts that aren’t cysts, you didn’t need to have them to be diagnosed, and the diagnostic goalposts have shifted depending on which expert panel you asked. And somehow, in the face of all that ambiguity, the medical response to a patient in a larger body was reliably, predictably: “Have you tried losing weight?”
The previous name was misleading from the start and, unsurprisingly, the patients paid the price.
The updated name, polyendocrine metabolic ovarian syndrome, was announced this May 2026, published in The Lancet, and presented at the European Congress of Endocrinology in Prague. It was the culmination of more than 14 years of global collaboration involving 56 patient and professional organizations, and roughly 22,000 stakeholders who participated in surveys and workshops worldwide.
The global name change was chosen to prioritize two things above all: scientific accuracy and avoiding stigma.
Here’s what the new terminology actually signals:
“Polyendocrine” acknowledges that this is fundamentally a condition of the endocrine system, the body’s chemical messenger network. The hormonal disruption is widespread, not localized to one organ.
“Metabolic” puts the metabolic dimension front and center, making it harder to separate the condition from the insulin resistance, cardiometabolic risk, and systemic effects that have been undertreated for years.
“Ovarian” keeps the ovaries in the picture without overstating their role. Acknowledging they’re involved without framing the whole condition around them.
Nothing about your body changed when this name dropped. If you had PCOS last year, you have PMOS now. Same diagnosis, same symptoms, same body, same fight. What changed is the framing, and, in theory, what that framing demands of the medical system.
Here’s the thing. We can acknowledge that better nomenclature matters in medicine AND still be clear-eyed about what it doesn’t fix.
The people who have been failed by PCOS care weren’t failed primarily because of the name. They were failed because of how providers think about bodies and, specifically, how they think about bodies of larger sizes.
The “just lose weight” problem is a cultural problem, not a naming problem or a you problem.
Patients with PCOS/PMOS have reported for years being told their symptoms would improve if they simply lost weight, exercised more, and ate better, as if they hadn’t already tried.
Providers have dismissed irregular menstrual periods, painful and unpredictable cycles, and metabolic symptoms in patients in larger bodies as things that would resolve on their own with weight loss. This is weight bias. It’s harmful. And it is not solved by rearranging letters in an acronym.
The research backs this up plainly. Studies on provider knowledge gaps have found that a significant percentage of physicians couldn’t even identify which diagnostic criteria they were using for PCOS. Meanwhile, people in smaller bodies who meet every diagnostic criterion have been told they couldn’t possibly have the condition because they didn’t “look” the part.
The PCOS name was already doing too much harm by making “cysts” and “ovaries” the whole story. But PMOS still doesn’t address the fact that providers are making decisions based on body size before they make decisions based on symptoms.
A person in a larger body walks in with irregular periods, elevated androgens, and insulin resistance and gets told to lose weight. A person in a smaller body walks in with the same panel and gets told it can’t be PCOS because they don’t fit the profile.
Both of these people are being failed. In different ways, but failed all the same.
We are genuinely glad that PMOS represents the hormonal and metabolic complexity of this condition. We’re glad the consensus process centered patient voices: 85% of patients and 76% of health professionals agreed the change was necessary. We’re glad the conversation is shifting.
And. And. And.
A name change doesn’t train providers to stop assuming that weight is the cause of everything wrong with a fat patient’s body. It doesn’t mandate that doctors order the right bloodwork before they give lifestyle advice. It doesn’t ensure that a patient in a larger body gets the same diagnostic workup as a patient in a smaller body presenting with the same symptoms. It doesn’t teach medical students to unlearn the anti-fat bias that research shows is disturbingly pervasive in healthcare settings.
Here’s what people with PMOS actually need from providers:
Irregular periods, excess androgen effects, and metabolic disruption deserve investigation regardless of weight. PMOS is not a condition of large bodies. It affects people across ALL body sizes and it is routinely missed in people in smaller bodies and routinely dismissed in people in larger bodies.
Weight loss is not a treatment. It is a lifestyle outcome that may or may not be possible, sustainable, or relevant to what is driving a patient’s symptoms. Insulin resistance, androgen excess, and hormonal disruption require real clinical care, not a referral to the nearest fad diet.
Insulin resistance in PMOS occurs in people across all body sizes. The cardiometabolic risks are real and require monitoring, not just a BMI calculation.
Nearly 70% of people with PCOS/PMOS don’t know they have it, according to the WHO. That’s not a patient failure. That’s a systemic one.
We hold space here for the complexity of living in a body that medicine has never taken seriously enough.
If you’ve been dismissed by providers who looked at your size before your symptoms, that dismissal was not your fault. If you’ve been handed a pamphlet about diet and exercise when what you needed was an endocrinology referral, that was a failure of care. If you’ve spent years trying to get answers for a condition that affects one in eight people but somehow remains deeply misunderstood in clinical practice, your frustration is completely valid.
PMOS is a better name than PCOS. It’s genuinely more accurate. And accurate language in medicine matters, it shapes how conditions are researched, funded, treated, and taught.
But language doesn’t heal the harm that has already been done. And it won’t prevent future harm until the culture of medicine changes, until the weight bias that lives inside clinical decision-making is named, confronted, and dismantled with the same rigor applied to renaming a syndrome.
A name change is a starting line, not a finish line.
You deserve providers who take your symptoms seriously, who understand the metabolic and hormonal complexity of PMOS, and who see your body as worthy of competent, compassionate care at whatever size.
That’s not a lot to ask. It’s the bare minimum. And we’ll keep saying so until the system catches up.
Megan is a weight inclusive registered dietitian and Certified Intuitive Eating Counselor. She is the founder and director of A Soft Place to Land, a multidisciplinary group practice based in Lehigh Valley, Pennsylvania that specializes in eating disorders, chronic dieting, and body image care. She is fiercely on a mission to be a loud advocate for ethical care of every BODY. Megan’s goal is to provide a weight inclusive and trauma informed safe space with an emphasis on social justice, fat liberation, self-exploration, and compassion. When she’s not taking down the patriarchy, you can find her spending time with her dogs outside, gardening, and painting plant pots!
Weight-inclusive and trauma-informed nutrition and therapy services.
Copyright © 2026. A Soft Place to Land. All rights reserved.
